Epigallocatechin gallate overcomes oxaliplatin resistance in colorectal cancer by suppressing NF-κB signaling and disrupting mitochondrial homeostasis
Bioorganic Chemistry · 2026-11 · 183 · 110581
DOI: 10.1016/j.bioorg.2026.110581 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-11. Verfasst von Zhiqiang Song und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal and Hernia Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, No. 42 Wenhua West Roa…. Hauptthemen laut MEDLINE: Catechin, NF-kappa B, Colorectal Neoplasms, Mitochondria. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Acquired resistance to oxaliplatin remains a major obstacle to the successful treatment of advanced colorectal cancer, highlighting the necessity for the development of novel strategies for restoring chemosensitivity. Epigallocatechin-3-gallate (EGCG), the principal polyphenol of green tea, exhibits diverse anticancer activities. This study investigated the efficacy of EGCG against oxaliplatin-resistant colorectal cancer cells, with particular emphasis on mitochondrial bioenergetics and NF-κB signaling. METHODS: Oxaliplatin-resistant HT-29, HCT116, and SW480 colorectal cancer cell lines were established through stepwise drug selection. Cell viability, colony formation, cell-cycle distribution, apoptosis, mitochondrial respiration, intracellular ATP production, gene expression assays, and xenograft models were employed to characterize the effects of EGCG. RESULTS: EGCG markedly restored oxaliplatin sensitivity in resistant colorectal cancer cells, significantly reducing cell viability and clonogenic capacity along with the induction of G2/M arrest and apoptosis. EGCG profoundly impaired mitochondrial bioenergetics by suppressing oxidative phosphorylation, glycolytic capacity, and ATP production. EGCG inhibited NF-κB activation and downregulated mitochondrial metabolic genes. Restoration of mitochondrial function by PGC1α overexpression partially reversed these effects, whereas concurrent activation of NF-κB signaling with TNF-α caused a more robust rescue, demonstrating a convergence between mitochondrial metabolism and NF-κB signaling in contributing to the resistant phenotype. Besides, EGCG significantly suppressed tumor growth and prolonged survival in oxaliplatin-resistant colorectal cancer xenografts. CONCLUSIONS: EGCG helped overcome oxaliplatin resistance by promoting apoptosis and inhibiting tumor progression through disruption of mitochondrial bioenergetics and suppression of NF-κB signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal and Hernia Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, No. 42 Wenhua West Road, Lixia District, Jinan City, Shandong Province 250011, China.
- Department of Pharmacy, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, No. 42 Wenhua West Road, Lixia District, Jinan City, Shandong Province 250011, China. Electronic address: xujun0535@126…
Zitieren
APA
Song, Z., & Xv, J. (2026). Epigallocatechin gallate overcomes oxaliplatin resistance in colorectal cancer by suppressing NF-κB signaling and disrupting mitochondrial homeostasis. Bioorganic Chemistry, 183, 110581. https://doi.org/10.1016/j.bioorg.2026.110581
Vancouver
Song Z, Xv J. Epigallocatechin gallate overcomes oxaliplatin resistance in colorectal cancer by suppressing NF-κB signaling and disrupting mitochondrial homeostasis. Bioorganic Chemistry. 2026;183:110581. doi:10.1016/j.bioorg.2026.110581
BibTeX
@article{Song2026,
author = {Song, Zhiqiang and Xv, Jun},
title = {Epigallocatechin gallate overcomes oxaliplatin resistance in colorectal cancer by suppressing NF-κB signaling and disrupting mitochondrial homeostasis},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {183},
pages = {110581},
doi = {10.1016/j.bioorg.2026.110581}
}
EUVIMED